{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:35:44Z","timestamp":1781955344140,"version":"3.54.5"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11914-017-0354-3","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T14:34:41Z","timestamp":1494513281000},"page":"76-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bone Pain and Muscle Weakness in Cancer Patients"],"prefix":"10.1007","volume":"15","author":[{"given":"Daniel P.","family":"Milgrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha L.","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas G.","family":"Koniaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Zimmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"issue":"4","key":"354_CR1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2049463714545136","volume":"8","author":"S Falk","year":"2014","unstructured":"Falk S, Bannister K, Dickenson AH. Cancer pain physiology. Br J Pain. 2014;8(4):154\u201362.","journal-title":"Br J Pain"},{"issue":"1\u20132","key":"354_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","volume":"69","author":"S Mercadante","year":"1997","unstructured":"Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1\u20132):1\u201318.","journal-title":"Pain"},{"key":"354_CR3","first-page":"4239","volume":"9","author":"XC Zhu","year":"2015","unstructured":"Zhu XC, et al. Advances in cancer pain from bone metastasis. Drug Des Devel Ther. 2015;9:4239\u201345.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"354_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1479972312471549","volume":"10","author":"KE Irwin","year":"2013","unstructured":"Irwin KE, et al. Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis. 2013;10(1):35\u201347.","journal-title":"Chron Respir Dis"},{"issue":"6","key":"354_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0305-7372(98)90005-6","volume":"24","author":"S Mercadante","year":"1998","unstructured":"Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24(6):425\u201332.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"354_CR6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejrad.2015.10.012","volume":"85","author":"MB Lange","year":"2016","unstructured":"Lange MB, et al. Diagnostic accuracy of imaging methods for the diagnosis of skeletal malignancies: a retrospective analysis against a pathology-proven reference. Eur J Radiol. 2016;85(1):61\u20137.","journal-title":"Eur J Radiol"},{"issue":"6","key":"354_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3413\/Nukmed-0730-15-03","volume":"54","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, et al. The added value of SPECT\/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma. Nuklearmedizin. 2015;54(6):255\u201361.","journal-title":"Nuklearmedizin"},{"issue":"12","key":"354_CR8","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.115.162610","volume":"56","author":"R Minamimoto","year":"2015","unstructured":"Minamimoto R, et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET\/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. 2015;56(12):1862\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"354_CR9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11307-011-0486-2","volume":"14","author":"A Iagaru","year":"2012","unstructured":"Iagaru A, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET\/CT, and (18)F FDG PET\/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14(2):252\u20139.","journal-title":"Mol Imaging Biol"},{"key":"354_CR10","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1038\/boneres.2015.24","volume":"3","author":"D Ulmert","year":"2015","unstructured":"Ulmert D, Solnes L, Thorek D. Contemporary approaches for imaging skeletal metastasis. Bone Res. 2015;3:15024.","journal-title":"Bone Res"},{"issue":"3","key":"354_CR11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jnci\/82.3.166","volume":"82","author":"IJ Fidler","year":"1990","unstructured":"Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82(3):166\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"354_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clon.2011.03.003","volume":"23","author":"T Middlemiss","year":"2011","unstructured":"Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol). 2011;23(6):387\u201392.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"15","key":"354_CR13","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","volume":"19","author":"GD Roodman","year":"2001","unstructured":"Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19(15):3562\u201371.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"354_CR14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.11132","volume":"97","author":"SM Kakonen","year":"2003","unstructured":"Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97(3 Suppl):834\u20139.","journal-title":"Cancer"},{"issue":"3","key":"354_CR15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/med.20224","volume":"32","author":"DJ Papachristou","year":"2012","unstructured":"Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev. 2012;32(3):611\u201336.","journal-title":"Med Res Rev"},{"issue":"2","key":"354_CR16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10(2):169\u201380.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"20 Pt 2","key":"354_CR17","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","volume":"12","author":"TA Guise","year":"2006","unstructured":"Guise TA, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 Pt 2):6213s\u20136s.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"354_CR18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tem.2011.02.007","volume":"22","author":"D Schramek","year":"2011","unstructured":"Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. 2011;22(5):188\u201394.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"354_CR19","first-page":"1","volume":"13","author":"UH Weidle","year":"2016","unstructured":"Weidle UH, et al. Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics. 2016;13(1):1\u201312.","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"354_CR20","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1172\/JCI71812","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest. 2014;124(4):1646\u201359.","journal-title":"J Clin Invest"},{"issue":"10","key":"354_CR21","first-page":"13217","volume":"8","author":"W Wu","year":"2015","unstructured":"Wu W, et al. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. Int J Clin Exp Pathol. 2015;8(10):13217\u201324.","journal-title":"Int J Clin Exp Pathol"},{"issue":"49","key":"354_CR22","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/onc.2011.187","volume":"30","author":"Y Min","year":"2011","unstructured":"Min Y, et al. C\/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene. 2011;30(49):4901\u20139.","journal-title":"Oncogene"},{"issue":"9","key":"354_CR23","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/0008-5472.CAN-06-2355","volume":"67","author":"T Hiraga","year":"2007","unstructured":"Hiraga T, et al. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007;67(9):4157\u201363.","journal-title":"Cancer Res"},{"issue":"4","key":"354_CR24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00432-012-1370-4","volume":"139","author":"YB Gao","year":"2013","unstructured":"Gao YB, et al. Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone. J Cancer Res Clin Oncol. 2013;139(4):669\u201379.","journal-title":"J Cancer Res Clin Oncol"},{"key":"354_CR25","doi-asserted-by":"crossref","unstructured":"Mohammad, K.S. and T.A. Guise, Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res. 2003. (415 Suppl): p. S67\u201374.","DOI":"10.1097\/01.blo.0000093047.96273.4e"},{"issue":"2","key":"354_CR26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-006-0045-1","volume":"8","author":"SG Thakkar","year":"2006","unstructured":"Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep. 2006;8(2):108\u201313.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"354_CR27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jcb.20735","volume":"97","author":"CL Hall","year":"2006","unstructured":"Hall CL, et al. Role of Wnts in prostate cancer bone metastases. J Cell Biochem. 2006;97(4):661\u201372.","journal-title":"J Cell Biochem"},{"key":"354_CR28","doi-asserted-by":"crossref","unstructured":"Mishra, S., et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget. 2015.","DOI":"10.18632\/oncotarget.6317"},{"issue":"11","key":"354_CR29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","volume":"7","author":"AE Mirrakhimov","year":"2015","unstructured":"Mirrakhimov AE. Hypercalcemia of malignancy: an update on pathogenesis and management. N Am J Med Sci. 2015;7(11):483\u201393.","journal-title":"N Am J Med Sci"},{"issue":"4","key":"354_CR30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","volume":"352","author":"AF Stewart","year":"2005","unstructured":"Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"354_CR31","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","volume":"97","author":"JJ Wysolmerski","year":"2012","unstructured":"Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab. 2012;97(9):2947\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"354_CR32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","volume":"9","author":"OS Nielsen","year":"1991","unstructured":"Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"354_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/SPC.0000000000000048","volume":"8","author":"PW Mantyh","year":"2014","unstructured":"Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care. 2014;8(2):83\u201390.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"4","key":"354_CR34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1526-4637.2000.00047.x","volume":"1","author":"P Honore","year":"2000","unstructured":"Honore P, Mantyh PW. Bone cancer pain: from mechanism to model to therapy. Pain Med. 2000;1(4):303\u20139.","journal-title":"Pain Med"},{"key":"354_CR35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00003086-200004000-00013","volume":"373","author":"DR Clohisy","year":"2000","unstructured":"Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res. 2000;373:104\u201314.","journal-title":"Clin Orthop Relat Res"},{"issue":"1\u20132","key":"354_CR36","first-page":"19","volume":"854","author":"HJ Gould 3rd","year":"2000","unstructured":"Gould 3rd HJ, et al. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res. 2000;854(1\u20132):19\u201329.","journal-title":"Brain Res"},{"issue":"1","key":"354_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0896-6273(02)00908-X","volume":"36","author":"RR Ji","year":"2002","unstructured":"Ji RR, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002;36(1):57\u201368.","journal-title":"Neuron"},{"issue":"1\u20132","key":"354_CR38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3959(02)00068-4","volume":"99","author":"K Obata","year":"2002","unstructured":"Obata K, et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain. 2002;99(1\u20132):121\u201332.","journal-title":"Pain"},{"issue":"2","key":"354_CR39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuroscience.2010.08.056","volume":"171","author":"WG Mantyh","year":"2010","unstructured":"Mantyh WG, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588\u201398.","journal-title":"Neuroscience"},{"issue":"7","key":"354_CR40","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/art.34385","volume":"64","author":"JR Ghilardi","year":"2012","unstructured":"Ghilardi JR, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012;64(7):2223\u201332.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"354_CR41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jpain.2010.12.016","volume":"12","author":"AP Bloom","year":"2011","unstructured":"Bloom AP, et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain. 2011;12(6):698\u2013711.","journal-title":"J Pain"},{"issue":"44","key":"354_CR42","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1523\/JNEUROSCI.3300-10.2010","volume":"30","author":"JM Jimenez-Andrade","year":"2010","unstructured":"Jimenez-Andrade JM, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649\u201356.","journal-title":"J Neurosci"},{"issue":"24","key":"354_CR43","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1523\/JNEUROSCI.19-24-10886.1999","volume":"19","author":"MJ Schwei","year":"1999","unstructured":"Schwei MJ, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19(24):10886\u201397.","journal-title":"J Neurosci"},{"issue":"2","key":"354_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3959(92)90049-H","volume":"48","author":"KL Syrjala","year":"1992","unstructured":"Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain. 1992;48(2):137\u201346.","journal-title":"Pain"},{"issue":"2","key":"354_CR45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000338579","volume":"7","author":"G Schneider","year":"2012","unstructured":"Schneider G, Voltz R, Gaertner J. Cancer pain management and bone metastases: an update for the clinician. Breast Care (Basel). 2012;7(2):113\u201320.","journal-title":"Breast Care (Basel)"},{"issue":"24","key":"354_CR46","first-page":"7343","volume":"62","author":"MA Sabino","year":"2002","unstructured":"Sabino MA, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 2002;62(24):7343\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"354_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/SPC.0000000000000043","volume":"8","author":"N Gough","year":"2014","unstructured":"Gough N, Miah AB, Linch M. Nonsurgical oncological management of cancer pain. Curr Opin Support Palliat Care. 2014;8(2):102\u201311.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"12","key":"354_CR48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634\u201342.","journal-title":"Circulation"},{"issue":"1\u20132","key":"354_CR49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pain.2007.06.026","volume":"132","author":"T King","year":"2007","unstructured":"King T, et al. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007;132(1\u20132):154\u201368.","journal-title":"Pain"},{"issue":"5","key":"354_CR50","first-page":"E547","volume":"16","author":"M Nishihara","year":"2013","unstructured":"Nishihara M, et al. Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician. 2013;16(5):E547\u201352.","journal-title":"Pain Physician"},{"issue":"3","key":"354_CR51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728214.2011.588600","volume":"16","author":"F Pantano","year":"2011","unstructured":"Pantano F, et al. New targets, new drugs for metastatic bone pain: a new philosophy. Expert Opin Emerg Drugs. 2011;16(3):403\u20135.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"12","key":"354_CR52","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14712598.6.12.1333","volume":"6","author":"D Santini","year":"2006","unstructured":"Santini D, et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther. 2006;6(12):1333\u201348.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"354_CR53","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60(11):2949\u201354.","journal-title":"Cancer Res"},{"issue":"13","key":"354_CR54","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T, et al. Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res. 2004;10(13):4559\u201367.","journal-title":"Clin Cancer Res"},{"issue":"15 Pt 1","key":"354_CR55","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","volume":"13","author":"D Santini","year":"2007","unstructured":"Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13(15 Pt 1):4482\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"354_CR56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","volume":"25","author":"B Vincenzi","year":"2005","unstructured":"Vincenzi B, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interf Cytokine Res. 2005;25(3):144\u201351.","journal-title":"J Interf Cytokine Res"},{"key":"354_CR57","unstructured":"Coleman, R.E. Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer. oncology (Williston Park). 2016. 30(8)."},{"key":"354_CR58","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","volume":"6","author":"N Raje","year":"2016","unstructured":"Raje N, et al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J. 2016;6:e378.","journal-title":"Blood Cancer J"},{"key":"354_CR59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","volume":"53","author":"A Lipton","year":"2015","unstructured":"Lipton A, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2015;53:75\u201383.","journal-title":"Eur J Cancer"},{"issue":"6","key":"354_CR60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clgc.2015.07.002","volume":"13","author":"MA Carducci","year":"2015","unstructured":"Carducci MA, et al. Atrasentan in patients with advanced renal cell carcinoma: a phase 2 trial of the ECOG-ACRIN cancer research group (E6800). Clin Genitourin Cancer. 2015;13(6):531\u20139. e1","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"354_CR61","first-page":"3465","volume":"8","author":"L Qiao","year":"2015","unstructured":"Qiao L, et al. Endothelin\u2014a receptor antagonists in prostate cancer treatment\u2014a meta-analysis. Int J Clin Exp Med. 2015;8(3):3465\u201373.","journal-title":"Int J Clin Exp Med"},{"key":"354_CR62","doi-asserted-by":"crossref","unstructured":"Bougioukli, S., et al. Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone, 2015.","DOI":"10.1016\/j.bone.2015.12.052"},{"issue":"4","key":"354_CR63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.15430\/JCP.2015.20.4.281","volume":"20","author":"SK Lee","year":"2015","unstructured":"Lee SK, et al. Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B ligand\/osteoprotegerin ratio in human osteoblastic cells. J Cancer Prev. 2015;20(4):281\u20136.","journal-title":"J Cancer Prev"},{"issue":"1","key":"354_CR64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","volume":"318","author":"N Rucci","year":"2006","unstructured":"Rucci N, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318(1):161\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"354_CR65","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/j.pain.0000000000000115","volume":"156","author":"DC Brown","year":"2015","unstructured":"\u2022 Brown DC, Agnello K, Iadarola MJ. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. Pain. 2015;156(6):1018\u201324. This paper proposes a promising novel therapy for CIBP","journal-title":"Pain"},{"key":"354_CR66","first-page":"1347","volume":"6","author":"M Cojoc","year":"2013","unstructured":"Cojoc M, et al. Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis. Onco Targets Ther. 2013;6:1347\u201361.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"354_CR67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11916-012-0271-1","volume":"16","author":"S Lutz","year":"2012","unstructured":"Lutz S. The role of radiation therapy in controlling painful bone metastases. Curr Pain Headache Rep. 2012;16(4):300\u20136.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"354_CR68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2012.12.009","volume":"106","author":"K Dennis","year":"2013","unstructured":"Dennis K, et al. Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials. Radiother Oncol. 2013;106(1):5\u201314.","journal-title":"Radiother Oncol"},{"issue":"1","key":"354_CR69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbo.2014.11.001","volume":"4","author":"R McDonald","year":"2015","unstructured":"McDonald R, et al. Quality of life after palliative radiotherapy in bone metastases: a literature review. J Bone Oncol. 2015;4(1):24\u201331.","journal-title":"J Bone Oncol"},{"issue":"1","key":"354_CR70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7150\/jca.13377","volume":"7","author":"MJ Wolanczyk","year":"2016","unstructured":"Wolanczyk MJ, Fakhrian K, Adamietz IA. Radiotherapy, bisphosphonates and surgical stabilization of complete or impending pathologic fractures in patients with metastatic bone disease. J Cancer. 2016;7(1):121\u20134.","journal-title":"J Cancer"},{"issue":"15","key":"354_CR71","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S1470-2045(15)00199-0","volume":"16","author":"E Chow","year":"2015","unstructured":"Chow E, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(15):1463\u201372.","journal-title":"Lancet Oncol"},{"issue":"2","key":"354_CR72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/107327481201900207","volume":"19","author":"HH Yu","year":"2012","unstructured":"Yu HH, Hoffe SE. Beyond the conventional role of external-beam radiation therapy for skeletal metastases: new technologies and stereotactic directions. Cancer Control. 2012;19(2):129\u201336.","journal-title":"Cancer Control"},{"issue":"2","key":"354_CR73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","volume":"54","author":"G Kothari","year":"2015","unstructured":"Kothari G, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54(2):148\u201357.","journal-title":"Acta Oncol"},{"issue":"3","key":"354_CR74","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2014.10.055","volume":"91","author":"H Kim","year":"2015","unstructured":"Kim H, et al. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Int J Radiat Oncol Biol Phys. 2015;91(3):556\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"354_CR75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.radonc.2013.09.004","volume":"110","author":"E Wong","year":"2014","unstructured":"Wong E, et al. Re-irradiation for painful bone metastases\u2014a systematic review. Radiother Oncol. 2014;110(1):61\u201370.","journal-title":"Radiother Oncol"},{"issue":"2","key":"354_CR76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/107327481201900208","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012;19(2):137\u201344.","journal-title":"Cancer Control"},{"issue":"6","key":"354_CR77","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1148\/rg.336125162","volume":"33","author":"A Napoli","year":"2013","unstructured":"Napoli A, et al. MR imaging-guided focused ultrasound for treatment of bone metastasis. Radiographics. 2013;33(6):1555\u201368.","journal-title":"Radiographics"},{"issue":"4","key":"354_CR78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.mric.2015.05.013","volume":"23","author":"T Kobus","year":"2015","unstructured":"Kobus T, McDannold N. Update on clinical magnetic resonance-guided focused ultrasound applications. Magn Reson Imaging Clin N Am. 2015;23(4):657\u201367.","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"20","key":"354_CR79","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2106\/00004623-201310160-00011","volume":"95","author":"RH Quinn","year":"2013","unstructured":"Quinn RH, et al. Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners. J Bone Joint Surg Am. 2013;95(20):1887\u201395.","journal-title":"J Bone Joint Surg Am"},{"issue":"13","key":"354_CR80","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1245\/s10434-014-4002-1","volume":"21","author":"TJ Wood","year":"2014","unstructured":"Wood TJ, et al. Surgical management of bone metastases: quality of evidence and systematic review. Ann Surg Oncol. 2014;21(13):4081\u20139.","journal-title":"Ann Surg Oncol"},{"key":"354_CR81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","volume":"7","author":"A Hameed","year":"2014","unstructured":"Hameed A, et al. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33\u201342.","journal-title":"Cancer Growth Metastasis"},{"issue":"3","key":"354_CR82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/os.12114","volume":"6","author":"PJ Rao","year":"2014","unstructured":"Rao PJ, et al. Minimally invasive percutaneous fixation techniques for metastatic spinal disease. Orthop Surg. 2014;6(3):187\u201395.","journal-title":"Orthop Surg"},{"issue":"1","key":"354_CR83","first-page":"14","volume":"1","author":"HS Smith","year":"2012","unstructured":"Smith HS. Painful boney metastases. Ann Palliat Med. 2012;1(1):14\u201331.","journal-title":"Ann Palliat Med"},{"issue":"2","key":"354_CR84","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0034-1373791","volume":"31","author":"RC Foster","year":"2014","unstructured":"Foster RC, Stavas JM. Bone and soft tissue ablation. Semin Intervent Radiol. 2014;31(2):167\u201379.","journal-title":"Semin Intervent Radiol"},{"key":"354_CR85","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-med-061509-131248","volume":"62","author":"S Dodson","year":"2011","unstructured":"Dodson S, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265\u201379.","journal-title":"Annu Rev Med"},{"key":"354_CR86","doi-asserted-by":"crossref","unstructured":"Sjoblom, B., et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016.","DOI":"10.1016\/j.clnu.2016.03.010"},{"key":"354_CR87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/bonekey.2015.59","volume":"4","author":"DL Waning","year":"2015","unstructured":"Waning DL, Guise TA. Cancer-associated muscle weakness: what\u2019s bone got to do with it? Bonekey Rep. 2015;4:691.","journal-title":"Bonekey Rep"},{"issue":"2","key":"354_CR88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S002966511500419X","volume":"75","author":"AM Ryan","year":"2016","unstructured":"Ryan AM, et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75(2):199\u2013211.","journal-title":"Proc Nutr Soc"},{"issue":"4","key":"354_CR89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jcsm.12031","volume":"6","author":"FE Marino","year":"2015","unstructured":"Marino FE, Risbridger G, Gold E. Activin-betaC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle. 2015;6(4):365\u201380.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"354_CR90","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, et al. Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45(10):2333\u201347.","journal-title":"Int J Biochem Cell Biol"},{"key":"354_CR91","doi-asserted-by":"crossref","unstructured":"Laurent, M.R., et al. Muscle-bone interactions: From experimental models to the clinic? A critical update. Mol Cell Endocrinol. 2015.","DOI":"10.1016\/j.mce.2015.10.017"},{"issue":"2","key":"354_CR92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89(2):381\u2013410.","journal-title":"Physiol Rev"},{"issue":"3","key":"354_CR93","first-page":"171","volume":"19","author":"D Sala","year":"2016","unstructured":"Sala D, Sacco A. Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr Opin Clin Nutr Metab Care. 2016;19(3):171\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"354_CR94","doi-asserted-by":"crossref","unstructured":"Zimmers, T.A., M.L. Fishel, and A. Bonetto. STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol, 2016.","DOI":"10.1016\/j.semcdb.2016.02.009"},{"key":"354_CR95","doi-asserted-by":"crossref","unstructured":"Rom, O. and A.Z. Reznick. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med, 2015.","DOI":"10.1016\/j.freeradbiomed.2015.12.031"},{"key":"354_CR96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.nutr.26.061505.111151","volume":"26","author":"VE Baracos","year":"2006","unstructured":"Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006;26:435\u201361.","journal-title":"Annu Rev Nutr"},{"issue":"5","key":"354_CR97","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.biocel.2004.10.003","volume":"37","author":"JM Argiles","year":"2005","unstructured":"Argiles JM, et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005;37(5):1084\u2013104.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"354_CR98","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1152\/japplphysiol.01474.2012","volume":"114","author":"MJ Toth","year":"2013","unstructured":"Toth MJ, et al. Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. J Appl Physiol (1985). 2013;114(7):858\u201368.","journal-title":"J Appl Physiol (1985)"},{"issue":"9","key":"354_CR99","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1089\/ars.2011.3965","volume":"15","author":"LA Gilliam","year":"2011","unstructured":"Gilliam LA, Clair DKS. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15(9):2543\u201363.","journal-title":"Antioxid Redox Signal"},{"issue":"3\u20134","key":"354_CR100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11864-010-0127-z","volume":"11","author":"NB Kumar","year":"2010","unstructured":"Kumar NB, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options in Oncol. 2010;11(3\u20134):107\u201317.","journal-title":"Curr Treat Options in Oncol"},{"key":"354_CR101","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","volume":"22","author":"JM Argiles","year":"2015","unstructured":"Argiles JM, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100\u20136.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"354_CR102","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000346446","volume":"58","author":"HS Wen","year":"2012","unstructured":"Wen HS, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy. 2012;58(6):461\u20137.","journal-title":"Chemotherapy"},{"issue":"4","key":"354_CR103","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335\u201345.","journal-title":"Lancet Oncol"},{"key":"354_CR104","doi-asserted-by":"crossref","unstructured":"\u2022 Temel, J.S., et al., Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 2016. This paper gives the results of two phase 3 trials, in which anamorelin had success in restoring lean muscle mass in patients with cachexia.","DOI":"10.1016\/S1470-2045(15)00558-6"},{"issue":"1","key":"354_CR105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","volume":"3","author":"S Busquets","year":"2012","unstructured":"Busquets S, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle. 2012;3(1):37\u201343.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"354_CR106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13539-014-0136-z","volume":"5","author":"N Ebner","year":"2014","unstructured":"Ebner N, et al. Highlights from the 7th cachexia conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014;5(1):27\u201334.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"354_CR107","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.29930","volume":"138","author":"M Toledo","year":"2016","unstructured":"Toledo M, et al. Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and beta-2 agonist. Int J Cancer. 2016;138(8):2021\u20139.","journal-title":"Int J Cancer"},{"issue":"6","key":"354_CR108","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1073\/pnas.0711074105","volume":"105","author":"AM Bellinger","year":"2008","unstructured":"Bellinger AM, et al. Remodeling of ryanodine receptor complex causes \u201cleaky\u201d channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A. 2008;105(6):2198\u2013202.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"354_CR109","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","volume":"14","author":"RC Smith","year":"2015","unstructured":"Smith RC, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14(7):1661\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"354_CR110","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jbmr.1969","volume":"28","author":"DJ DiGirolamo","year":"2013","unstructured":"DiGirolamo DJ, Kiel DP, Esser KA. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res. 2013;28(7):1509\u201318.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"354_CR111","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","volume":"20","author":"DL Waning","year":"2014","unstructured":"Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 2014;20(12):3071\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"354_CR112","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410\u201321.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"39","key":"354_CR113","doi-asserted-by":"crossref","first-page":"E3713","DOI":"10.1073\/pnas.1309907110","volume":"110","author":"YS Lee","year":"2013","unstructured":"Lee YS, Lee SJ. Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2. Proc Natl Acad Sci U S A. 2013;110(39):E3713\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"354_CR114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s004410051265","volume":"296","author":"H Ohuchi","year":"1999","unstructured":"Ohuchi H, Noji S. Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Cell Tissue Res. 1999;296(1):45\u201356.","journal-title":"Cell Tissue Res"},{"issue":"6","key":"354_CR115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1172\/JCI0215463","volume":"110","author":"S Yakar","year":"2002","unstructured":"Yakar S, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110(6):771\u201381.","journal-title":"J Clin Invest"},{"issue":"3","key":"354_CR116","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1359\/JBMR.051203","volume":"21","author":"MW Hamrick","year":"2006","unstructured":"Hamrick MW, et al. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res. 2006;21(3):477\u201383.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"354_CR117","first-page":"56","volume":"10","author":"MN Elkasrawy","year":"2010","unstructured":"Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10(1):56\u201363.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"354_CR118","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ydbio.2011.06.002","volume":"356","author":"Y Bren-Mattison","year":"2011","unstructured":"Bren-Mattison Y, Hausburg M, Olwin BB. Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev Biol. 2011;356(2):486\u201395.","journal-title":"Dev Biol"},{"issue":"11","key":"354_CR119","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning DL, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262\u201371.","journal-title":"Nat Med"},{"issue":"50","key":"354_CR120","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","volume":"102","author":"SJ Lee","year":"2005","unstructured":"Lee SJ, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102(50):18117\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"354_CR121","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1096\/fj.13-245894","volume":"28","author":"JL Chen","year":"2014","unstructured":"Chen JL, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28(4):1711\u201323.","journal-title":"FASEB J"},{"issue":"4","key":"354_CR122","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531\u201343.","journal-title":"Cell"},{"issue":"2","key":"354_CR123","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.exger.2012.11.004","volume":"48","author":"M Bowser","year":"2013","unstructured":"Bowser M, et al. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol. 2013;48(2):290\u20137.","journal-title":"Exp Gerontol"},{"issue":"8","key":"354_CR124","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm.1943","volume":"15","author":"M Korpal","year":"2009","unstructured":"Korpal M, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960\u20136.","journal-title":"Nat Med"},{"issue":"12","key":"354_CR125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.18632\/aging.100520","volume":"4","author":"S Hubackova","year":"2012","unstructured":"Hubackova S, et al. IL1- and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. Aging (Albany NY). 2012;4(12):932\u201351.","journal-title":"Aging (Albany NY)"},{"issue":"17","key":"354_CR126","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","volume":"280","author":"S Schiaffino","year":"2013","unstructured":"Schiaffino S, et al. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280(17):4294\u2013314.","journal-title":"FEBS J"},{"issue":"9","key":"354_CR127","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/jcm4091741","volume":"4","author":"T Kagiya","year":"2015","unstructured":"Kagiya T. MicroRNAs and osteolytic bone metastasis: the roles of MicroRNAs in tumor-induced osteoclast differentiation. J Clin Med. 2015;4(9):1741\u201352.","journal-title":"J Clin Med"},{"issue":"1","key":"354_CR128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2005.10.014","volume":"69","author":"TH Burne","year":"2006","unstructured":"Burne TH, et al. Swimming behaviour and post-swimming activity in vitamin D receptor knockout mice. Brain Res Bull. 2006;69(1):74\u20138.","journal-title":"Brain Res Bull"},{"issue":"4","key":"354_CR129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.12717\/DR.2014.18.4.197","volume":"18","author":"RK Mongre","year":"2014","unstructured":"Mongre RK, et al. A new paradigm to mitigate osteosarcoma by regulation of microRNAs and suppression of the NF-kappaB signaling Cascade. Dev Reprod. 2014;18(4):197\u2013212.","journal-title":"Dev Reprod"},{"issue":"4","key":"354_CR130","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ccr.2013.09.008","volume":"24","author":"B Ell","year":"2013","unstructured":"Ell B, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24(4):542\u201356.","journal-title":"Cancer Cell"},{"issue":"5","key":"354_CR131","doi-asserted-by":"crossref","first-page":"e37361","DOI":"10.1371\/journal.pone.0037361","volume":"7","author":"S Pollari","year":"2012","unstructured":"Pollari S, et al. Identification of microRNAs inhibiting TGF-beta-induced IL-11 production in bone metastatic breast cancer cells. PLoS One. 2012;7(5):e37361.","journal-title":"PLoS One"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-017-0354-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T14:22:51Z","timestamp":1692800571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-017-0354-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s11914-017-0354-3","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}